阿齐思罗米可以减少患有囊性纤维化症的婴儿的支气管壁加厚
Yuxin Chen1, Jean-Paul Charbonnier2, Eleni-Rosalina Andrinopoulou3
1Department of Paediatrics, Division of Respiratory Medicine and Allergology, Sophia Children's Hospital, Erasmus MC, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
概括
在患有囊性纤维化 (CF) 的婴儿中,阿兹罗米辛治疗减少了支气管壁的厚度,并可能改善肺 perfusion,如先进的CT扫描分析所示. 这一发现为早期CF管理提供了新的见解.
科学领域:
- 儿科肺病学 儿科肺病学
- 医疗成像医学成像
- 药理学 药理学是指药理学的学科.
背景情况:
- 之前的研究表明,阿兹胺在患有囊性纤维化 (CF) 的婴儿中具有临床益处,但对CT-score没有影响.
- 用自动支气管动脉 (BA) 分析对CT扫描进行了重新分析,以调查微妙的结构变化.
研究的目的:
- 用先进的CT成像分析重新评估阿齐思罗米对患有CF的婴儿呼吸道结构变化的影响.
- 为了评估支气管壁厚度和气道尺寸与动脉大小和低衰减区域的关系.
主要方法:
- 在228名婴儿 (12个月和36个月) 的吸气和呼气CT扫描中,使用自动BA分析进行了分析.
- 测量包括支气管外壁 (Bout),内壁 (Bin),动脉 (A) 和支气管壁厚度 (Bwt),并计算了扩大和加厚的比率.
- 量化了低衰减区域 (LAR),混合效应模型比较了36个月后阿齐思罗米辛和安慰剂组之间的结果.
主要成果:
- 阿兹罗米辛组的支气管壁面积与外围面积比率明显较低 (Bwa/Boa,p = 0.0034) 和支气管内壁与动脉比率较高 (Bin/A,p = 0.001).
- 观察到支气管外壁与动脉比率 (Bout/A,p = 0.0088) 的增加,归因于动脉直径的减少与LAR的减少相关.
结论:
- 在患有CF的婴儿中,阿齐思罗米辛治疗与支气管壁厚度的减少有关.
- 这些发现表明,阿齐思罗米对该群体的肺 perfusion 有潜在的积极影响,需要进一步调查.
相关概念视频
Cystic Fibrosis: Management
158
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
158
Antiasthma Drugs: Leukotriene Modifiers
282
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
282
Cystic Fibrosis: Pathogenesis
226
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
226
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
277
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
277
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
284
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
284
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
240
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
240


